News Lunit Inc.

Equities

A328130

KR7328130000

End-of-day quote Korea S.E. Other stock markets 23:00:00 23/06/2024 BST			5-day change	1st Jan Change
45,000 ^KRW	-2.81%		-9.27%	-45.05%

05-31	Lunit Inc. announced that it has received KRW 171.5 billion in funding from a group of investors	CI
05-24	Lunit to Showcase 7 Studies at Asco 2024, Including Ai Innovations in Her2 Quantification, and Multimodal Predictive Models for Immunotherapy Response	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lunit Inc. announced that it has received KRW 171.5 billion in funding from a group of investors	05-30	CI
Lunit to Showcase 7 Studies at Asco 2024, Including Ai Innovations in Her2 Quantification, and Multimodal Predictive Models for Immunotherapy Response	05-24	CI
Lunit Acquires New Zealand's Volpara Health Technologies	05-23	MT
Lunit Inc. completed the acquisition of Volpara Health Technologies Limited from Harbour Asset Management Limited and others.	05-12	CI
Volpara to Delist After Court Approves Acquisition by Lunit	05-03	MT
Lunit Wins Shareholder Approval for Volpara Health Takeover	04-16	MT
Volpara Health Technologies Secures Approval for Lunit’s Proposed Takeover	04-12	MT
Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals	04-08	CI
Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients	03-27	AQ
Lunit Announces Publication of New Study Featuring Lunit SCOPE IO	03-26	CI
Lunit Announces Two Commercial Deals Signal its Expansion in Europe	03-18	CI
Lunit SCOPE AI Enhances Pathologist Concordance and Accuracy in HER2, ER, and PR Assessment, New Study in Breast Cancer Research	03-15	AQ
Lunit Inc. Receives Two Supply Contracts That Mark Its Strategic Expansion into the East and Southeast Asian Region	03-11	CI
Lunit Presents Seven Study Results at ECR 2024, Showcasing AI's Robust Performance in Diverse Clinical Settings	02-29	AQ
New Study Demonstrates Predictive Value of Lunit SCOPE IO to Predict Outcomes of Immune Checkpoint Inhibitor Therapy across Diverse Tumors, published in the JITC	02-19	AQ
Lunit INSIGHT CXR Excels in Long Nodule Detection, Exceptional Performance in Head-to-Head Study published in Radiology	01-18	AQ
Lunit Announces Three-Year Supply Contract with Samsung Electronics	01-16	CI
GC Cell Signs Agreement with Lunit for AI-Powered Cancer Treatment	12-26	MT
Lunit to Acquire Volpara, Scheme Implementation Agreement Signed	12-15	AQ
Lunit to Take Over Volpara Health; Lunit Shares Decline 4%	12-15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Lunit Inc.

Equities

A328130

KR7328130000

Summary

Filters